Please ensure Javascript is enabled for purposes of website accessibility

3 Things Every Investor Should Know About Pfizer's Dividend

By Keith Speights - Jul 17, 2021 at 5:08AM

Key Points

  • There are only a few healthcare stocks that offer a higher dividend yield than Pfizer does.
  • Pfizer boasts an impressive track record of consecutive quarterly dividend payments.
  • The company's dividend is likely to increase in the future.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Hint: There's a lot to like.

Most companies don't make it to the ripe old age of 172. If they do, they usually don't become one of the most talked-about organizations in the world. But most companies aren't Pfizer (PFE 3.77%)

The big drugmaker helped change the world for the better with the COVID-19 vaccine that it developed with partner BioNTech. Thanks mainly to this vaccine, Pfizer ranks as the most popular healthcare stock among Robinhood investors. It's also in the top seven companies in the world with the best corporate reputation. 

However, if I had to pick one thing other than its COVID-19 vaccine that makes Pfizer stand out, my vote would be for its dividend. Here are three things every investor should know about Pfizer's dividend.

A bag with "Dividends" printed on it underneath an umbrella.

Image source: Getty Images.

1. It offers one of the most attractive yields in the healthcare sector

There are nearly 1,200 stocks in the healthcare sector. Only six of them have dividend yields that are higher than Pfizer's yield of 3.9%. 

Dividend yield is simply the percentage of annual dividends paid divided by the stock price. Yield goes up as the stock goes down and vice versa. This inverse relationship makes Pfizer's dividend yield stand out even more. Why? Over the last 12 months, its share price has risen more than any of the six healthcare stocks with higher dividend yields.

Pfizer's COVID-19 vaccine was certainly a key factor behind the stock outperforming the other top healthcare dividend stocks. However, the company's merger of its Upjohn unit with Mylan late last year also likely helped. The deal moved a basket of low- and no-growth drugs that have lost exclusivity out of Pfizer's lineup.

2. It's dependable

Where were you in 1938? Many of us weren't even alive at that point. Pfizer, though, was already a major drugmaker that paid dividends to its shareholders. And it's paid a dividend every quarter since then. When the company's third-quarter dividend is distributed in September, it will mark the 331st consecutive quarterly dividend paid by Pfizer. 

With that kind of track record, it's fair to say that Pfizer's dividend is dependable. Granted, the company did cut its dividend payout back in 2009. This move was made in connection with Pfizer's acquisition of Wyeth. However, the company quickly returned to its previous practice of annual dividend hikes.

Pfizer initially thought that it would reduce its dividend slightly due to the spin-off of Upjohn. There wouldn't have been a net effect for the company's shareholders prior to the transaction, though, because Viatris, the new entity created from the merger of Upjohn and Mylan, initiated its own dividend.

Ultimately, though, Pfizer didn't have to cut its dividend at all. The massive sales for its COVID-19 vaccine enabled the company to keep the dividend at its previous level despite losing the cash flow that had been generated by Upjohn.

3. It's likely to increase

The odds appear to be pretty good that Pfizer's dividend will increase going forward. For one thing, the company's management team remains committed to the dividend program. In Pfizer's first-quarter conference call, CFO Frank D'Amelio said that annual dividend increases were expected to continue "for the foreseeable future." 

It's a lot easier for a company to boost its dividend payout when its earnings are growing. And that seems likely to happen for Pfizer. Wall Street analysts project that the drugmaker's earnings will increase by an average of more than 11.5% annually over the next five years. 

The emergence of new coronavirus variants, including the highly transmissible delta variant, could fuel increased and sustained demand for Pfizer's COVID-19 vaccine. Pfizer's lineup also includes several other products with strong sales growth, such as blood thinner Eliquis, transthyretin amyloid cardiomyopathy drug Vyndaqel, autoimmune disease drug Xeljanz, and prostate cancer drug Xtandi.

Over the longer term, Pfizer could see even more growth from its pipeline candidates. As of early May, the company had 99 experimental drugs in clinical development, including 22 late-stage programs. 

A little something extra 

In Louisiana, there's a tradition known as lagniappe. It's where you get a little something extra thrown in. With this practice in mind, I'll give you one additional thing to know about Pfizer's dividend.

If you had owned shares of Pfizer over the last 10 years and reinvested the dividends, your total return would have been almost twice the returns the stock generated without dividend reinvestment. Pfizer's dividend could provide a lot of something extra for investors who buy and hold the big pharma stock.

Keith Speights owns shares of Pfizer and Viatris Inc. The Motley Fool recommends Viatris Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.11 (3.77%) $1.82
BioNTech SE Stock Quote
BioNTech SE
BNTX
$160.35 (1.11%) $1.76
Viatris Inc. Stock Quote
Viatris Inc.
VTRS
$11.13 (1.55%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.